Wegovy vs Saxenda Side-Effect Profile Head-to-Head

How These Two Drugs Actually Work

Both drugs mimic glucagon-like peptide-1 (GLP-1), a gut hormone that slows gastric emptying, reduces appetite signaling in the hypothalamus, and stimulates glucose-dependent insulin release. That shared mechanism explains why their side-effect signatures look similar on paper. The pharmacokinetic differences are large, though: semaglutide has a half-life of approximately 165 hours, enabling once-weekly dosing, while liraglutide's half-life is roughly 13 hours, requiring daily injection [1].

Receptor Binding and Duration

Semaglutide binds the GLP-1 receptor with higher affinity and resists degradation by dipeptidyl peptidase-4 (DPP-4) more effectively than liraglutide. This longer receptor occupancy may account for its greater efficacy signal and could also explain slightly higher rates of certain GI effects at the comparator doses studied in trials [2].

Dose Titration Schedules

Wegovy titrates from 0.25 mg weekly up to 2.4 mg weekly over 16 weeks. Saxenda titrates from 0.6 mg daily to 3.0 mg daily over 5 weeks. The slower titration schedule for Wegovy was designed specifically to reduce early GI burden, a design choice reflected in the STEP-1 protocol [1]. Patients on Saxenda reach their maintenance dose in about one-third the time, which may compress the window in which the body adapts to GI effects.

Gastrointestinal Side Effects: The Shared Core Problem

Nausea is the defining tolerability issue for both drugs. In STEP-1 (N=1,961), 44.2% of semaglutide-treated participants reported nausea versus 16.0% on placebo [1]. In SCALE Obesity and Prediabetes (N=3,731), nausea occurred in 39.3% of liraglutide-treated participants versus 14.1% on placebo [3]. Neither rate is trivial. Both are transient for most patients, peaking in the first four to eight weeks of each new dose increment.

Nausea and Vomiting Rates Compared

Vomiting rates diverge more than nausea rates. STEP-1 reported vomiting in 24.5% of the semaglutide group [1]. SCALE reported vomiting in 15.7% of the liraglutide group [3]. The absolute difference of roughly 9 percentage points is clinically meaningful for patients with low vomiting tolerance or jobs that require operating machinery. Diarrhea affected 29.7% on semaglutide in STEP-1 [1] versus 20.9% on liraglutide in SCALE [3].

Constipation

Constipation runs in the opposite direction relative to diarrhea. STEP-1 documented constipation in 24.2% of the semaglutide group [1], compared with 19.4% in the liraglutide group in SCALE [3]. Slowing of gastric motility by GLP-1 receptor agonists likely drives this effect, and adequate hydration plus dietary fiber are first-line management steps before considering any pharmacologic intervention.

Discontinuation Due to GI Events

GI adverse events led to treatment discontinuation in approximately 7% of semaglutide participants in STEP-1 [1] and in 9.9% of liraglutide participants in SCALE [3]. This is a counterintuitive finding given Wegovy's higher vomiting rate: the longer titration schedule for semaglutide may have allowed more patients to adapt before reaching peak dose, reducing the rate of early dropout. Prescribers should note that this comparison is cross-trial and not from a head-to-head randomized design.

Injection-Site Reactions

Saxenda, dosed daily, produces more cumulative injection-site exposures per year (365 injections vs approximately 52 for Wegovy). The SCALE trial recorded injection-site reactions in 13.9% of liraglutide participants [3]. STEP-1 reported injection-site reactions in 2.0% of the semaglutide group [1]. The difference is large and almost certainly reflects injection frequency rather than any intrinsic difference in excipient irritation. Patients who report needle fatigue or local bruising on Saxenda often tolerate Wegovy's weekly schedule more easily.

Cardiovascular and Heart-Rate Effects

Both GLP-1 receptor agonists produce a modest increase in resting heart rate. In STEP-1, mean heart rate increased by approximately 1 to 4 beats per minute with semaglutide 2.4 mg [1]. In SCALE, liraglutide 3 mg produced a mean heart rate increase of approximately 2.4 beats per minute versus placebo [3]. The FDA labels for both drugs note this signal and recommend evaluation in patients with known arrhythmia or baseline tachycardia [4, 5].

Blood Pressure

STEP-1 demonstrated a mean systolic blood pressure reduction of approximately 6 mmHg with semaglutide [1]. SCALE showed a comparable reduction of approximately 3 mmHg with liraglutide [3]. Both effects are considered secondary benefits for patients with obesity-related hypertension, though neither drug is approved for blood pressure management.

Cardiovascular Outcome Data

Long-term cardiovascular outcome data at the weight-loss doses are limited for both agents. The SELECT trial (N=17,604) examined semaglutide 2.4 mg specifically in patients with obesity and established cardiovascular disease, reporting a 20% relative risk reduction in major adverse cardiovascular events versus placebo [6]. No equivalent large cardiovascular outcome trial has been completed for liraglutide 3 mg in the weight-management indication, though the LEADER trial studied liraglutide 1.8 mg in type 2 diabetes patients and showed cardiovascular benefit at that lower dose [7].

Gallbladder and Pancreatic Safety

Rapid weight loss itself increases cholelithiasis risk, and GLP-1 receptor agonists slow gallbladder emptying. In STEP-1, cholelithiasis occurred in 2.6% of semaglutide participants versus 1.2% on placebo [1]. In SCALE, gallbladder disorders (including cholelithiasis and cholecystitis) occurred in 3.8% of liraglutide participants versus 2.3% on placebo [3]. These rates are modest in absolute terms but worth discussing with patients who have a prior history of gallstones.

Pancreatitis

Acute pancreatitis is listed in both FDA labels as a risk requiring treatment discontinuation if diagnosed [4, 5]. Rates in STEP-1 were 0.1% with semaglutide versus 0.1% with placebo [1]. SCALE reported pancreatitis in 0.3% with liraglutide versus 0.1% with placebo [3]. Neither drug should be initiated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), per both labels.

Thyroid C-Cell Tumor Warning

Rodent studies for both semaglutide and liraglutide showed dose-dependent thyroid C-cell tumors, resulting in a black-box warning on both FDA labels [4, 5]. Human relevance remains uncertain. A 2023 analysis published in Diabetes Care covering more than 145,000 GLP-1 receptor agonist users found no statistically significant increase in thyroid cancer incidence compared with other weight-loss medications, though the authors noted the observation period may be too short to detect long-latency tumors [8].

Psychiatric and Neurological Adverse Events

Suicidal Ideation

In 2023, the European Medicines Agency and FDA both reviewed signals of suicidal ideation reported with GLP-1 receptor agonists, including both semaglutide and liraglutide. A subsequent FDA review of clinical trial data did not find a causal association, and updated labeling guidance does not require a specific black-box warning for either drug on this basis [9]. Prescribers should still conduct standard depression screening as part of obesity management per standard of care.

Headache and Fatigue

STEP-1 reported headache in 13.9% of semaglutide participants [1]. SCALE reported headache in 13.2% of liraglutide participants [3]. Both rates are numerically close and likely reflect caloric restriction effects rather than direct drug pharmacology, though this cannot be fully disentangled in the trial data.

Drug Tolerability: Who Struggles More?

The following clinical decision framework synthesizes the cross-trial tolerability data into three patient profiles that may help guide selection:

Profile 1: Tolerability-first patient. A patient with a history of severe morning nausea, gastroparesis risk factors, or a daily-schedule sensitivity to injection timing may tolerate Wegovy's weekly schedule better. The 16-week titration gives more adaptation time, and one missed weekly dose is clinically less new than a missed daily dose.

Profile 2: Needle-averse or skin-reaction-prone patient. Saxenda's daily dosing means approximately 313 additional injections per year compared with Wegovy. Patients with prior local reactions to subcutaneous insulin or other injectables tend to report higher injection-site irritation with Saxenda's frequency.

Profile 3: Patient with prior GI history. Patients with irritable bowel syndrome or chronic nausea disorders face meaningful GI burden with either agent. STEP-1 and SCALE data both suggest the first eight weeks carry the highest GI event rates [1, 3]. A slow Wegovy titration may allow more dose-flexibility pauses than Saxenda's compressed schedule.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI <27 with at least one weight-related comorbidity, and note that agent selection should account for individual side-effect risk factors and patient preference [10].

Weight Efficacy in Context of Tolerability

Efficacy and tolerability are not independent variables. A drug with better tolerability but lower efficacy may still be the better clinical choice if the alternative is discontinued in the first 90 days. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [1]. SCALE (N=3,731) showed liraglutide 3 mg produced 8.0% mean body-weight loss at 56 weeks versus 2.6% for placebo (P<0.001) [3].

As noted in STEP-1, "the mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% in the placebo group (estimated treatment difference, -12.4 percentage points; 95% confidence interval, -13.4 to -11.5; P<0.001)" [1].

The SCALE investigators similarly stated, "at week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, as compared with 2.8±6.5 kg in the placebo group" [3].

That difference in weight loss (roughly 6 to 7 percentage points between the two drugs) is large enough to matter for comorbidity reduction, particularly for metabolic syndrome components and sleep apnea severity. Prescribers should weigh this against the higher vomiting rate seen with Wegovy in STEP-1.

Switching Between Drugs

Patients occasionally need to switch from one agent to the other, either due to intolerance, insurance formulary changes, or inadequate weight response. No published randomized trial has evaluated an optimized switch protocol between semaglutide 2.4 mg and liraglutide 3 mg specifically. FDA labeling does not specify a washout period for switching within the GLP-1 receptor agonist class [4, 5].

In clinical practice, most obesity medicine specialists observe a brief overlap gap of one to two weeks when switching from the weekly semaglutide to daily liraglutide, given the long half-life of semaglutide (approximately 165 hours). Starting liraglutide at the lowest titration dose (0.6 mg daily) immediately after the last semaglutide dose is a practical approach used by many prescribers, though this is based on pharmacokinetic reasoning rather than clinical trial data. Patients switching in this direction may experience compounded GI effects during the overlap window and should be counseled accordingly.

Switching from Saxenda to Wegovy due to GI intolerance requires recognizing that Wegovy's GI rates are not lower across the board. Vomiting in particular is more frequent with semaglutide. Patients who switched because of vomiting on Saxenda should be specifically counseled before starting Wegovy.

Cost, Insurance, and Formulary Context

Neither drug's side-effect profile exists in a vacuum. Formulary access shapes what patients actually use, and cost-related non-adherence can itself create a safety signal (stopping and restarting a GLP-1 receptor agonist repeatedly increases early GI exposure with each re-titration). As of 2025, both drugs face significant out-of-pocket barriers without insurance coverage. The average list price for Wegovy exceeds $1,300 per month, while Saxenda lists at approximately $1,400 per month, though actual paid costs vary by plan and manufacturer coupon availability. These figures are not sourced from clinical trials and should be verified at the point of prescribing.